Business
information report
1. Summary Information
|
|
|
Country |
India |
|
Company Name |
HLL LIFECARE LIMITED |
Principal Name 1 |
Mr. Ayyappan Madhavan Nair |
|
Status |
Good |
Principal Name 2 |
Mr. Rakesh Prasad Khandelwal |
|
|
|
Registration # |
09-002621 |
|
Street Address |
Hill Bhavan, Mahilamandiram Road, Poojapura P. O.,
Thiruvananathapuram–695012, Kerala |
||
|
Established Date |
01.03.1966 |
SIC Code |
-- |
|
Telephone# |
91-471-2341149 |
Business Style 1 |
Manufacturer |
|
Fax # |
91-471-2340739 |
Business Style 2 |
Trader |
|
Homepage |
Product Name 1 |
Male Contraceptive Rubber Condoms |
|
|
# of employees |
Not Available |
Product Name 2 |
Copper T |
|
Paid up capital |
Rs,
155,350,000/- |
Product Name 3 |
Mala D/N |
|
Shareholders |
Government – 100% |
Banking |
State Bank of
India |
|
Public Limited Corp. |
No |
Business Period |
46 Years |
|
IPO |
No |
International Ins. |
- |
|
Public Enterprise |
No |
Rating |
A (64) |
|
Related
Company |
|||
|
Relation
|
Country
|
Company
Name |
CEO |
|
-- |
-- |
-- |
-- |
|
Note |
- |
||
2. Summary
Financial Statement
|
Balance Sheet as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Assets |
Liabilities |
||
|
Current Assets |
3,366,714,000 |
Current Liabilities |
2,054,581,000 |
|
Inventories |
573,931,000 |
Long-term Liabilities |
1,605,979,000 |
|
Fixed Assets |
1,167,458,000 |
Other Liabilities |
124,602,000 |
|
Deferred Assets |
0,000 |
Total Liabilities |
3,785,162,000 |
|
Invest& other Assets |
236,659,000 |
Retained Earnings |
1,404,250,000 |
|
|
|
Net Worth |
1,559,600,000 |
|
Total Assets |
5,344,762,000 |
Total Liab. & Equity |
5,344,762,000 |
|
Total Assets (Previous Year) |
9,923,335,000 |
|
|
|
P/L Statement as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Sales |
5,170,000,000 |
Net Profit |
184,300,000 |
|
Sales(Previous yr) |
4,400,629,000 |
Net Profit(Prev.yr) |
149,339,000 |
MIRA
INFORM REPORT
|
Report Date : |
17.03.2012 |
IDENTIFICATION DETAILS
|
Name : |
HLL LIFECARE LIMITED |
|
|
|
|
Formerly Known
As : |
HINDUSTAN LATEX LIMITED |
|
|
|
|
Registered
Office : |
Hill Bhavan, Mahilamandiram Road, Poojapura P. O., Thiruvananathapuram–695012, Kerala |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2011 |
|
|
|
|
Date of
Incorporation : |
01.03.1966 |
|
|
|
|
Com. Reg. No.: |
09-002621 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs. 155.350 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U25193KL1966GOI002621 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
BLRH02231F |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACH5598K |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturing, trading and marketing of condoms for National Family Planning programme of Government of India and manufacture of Oral Contraceptives like Birth Control Pills and Intra Uterine devices and health care products like Blood Bags, Hydrocephalus Shuts, Surgical Gloves and Surgical Sutures. |
|
|
|
|
No. of Employees
: |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
A (64) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 6200000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an old and well established government of India company
having fine track. Financial position of the company appears to be good.
Trade relations are reported as fair. Business is active. Payments are
reported to be regular and as per commitments. The company can be considered good for normal business dealings at
usual trade terms and conditions. It can be regarded as a promising business partner in a medium to long
run. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
LOCATIONS
|
Registered Office / Corporate Head Office: |
Hill Bhavan, Mahilamandiram Road, Poojapura P. O.,
Thiruvananathapuram–695012, Kerala, India |
|
Tel. No.: |
91-471-2341149/2341219/2341352/2354949 |
|
Fax No.: |
91-471-2340739/2340125/2358890/2356739 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory 1 : |
Peroorkada
Factory, Thiruvananthapuram Peroorkada, Trivandrum, Kerala, Thiruvananthpuram-685005, Kerala,
India |
|
Tel. No.: |
91-471-2437270 / 2433602 |
|
Fax No.: |
91-471-2435013 / 2435013 |
|
E-Mail : |
|
|
|
|
|
Factory 2 : |
Akkulam Factory, Thiruvananthapuram Akkulam, Thiruvananthapuram, Kerala, India |
|
Tel. No.: |
91-471-2441384, 2442641 |
|
Fax No.: |
91-471-2441383 |
|
E-Mail : |
|
|
|
|
|
Factory 3 : |
Kanagala Factory,
Belgaum Kangala, Belgaum- 591225, Karnataka, India |
|
Tel. No.: |
91-8333-279244/ 279207 |
|
Fax No.: |
91-8333-279245/ 279206 |
|
E-Mail : |
|
|
|
|
|
Factory 4 : |
Mensar Factory,
Gurgaon Plot No. 71, Sector-7, IMT, Manesar, Gurgaon-122051, Haryana, India |
|
Tel. No.: |
91-124-4030949 |
|
Fax No.: |
91-124-4030949 |
|
E-Mail : |
|
|
|
|
|
Factory 5 : |
Kakkanand Factory,
Cochin Plot No. 16-A/1, Cochin Special Economic Zone, Kakkanand,
Cochin-682037, Karnataka, India |
|
Tel. No.: |
91-484-2413332/ 241 |
|
Fax No.: |
91-484-2413293 |
|
E-Mail : |
|
|
|
|
|
Factory 6 : |
Procurement and
Consultancy Services B-14 A, Sector-62, Noida-201301, Uttar Pradesh, India |
|
Tel. No.: |
91-120-4071500 |
|
Fax No.: |
91-120-4071513 |
|
E-Mail : |
|
|
|
|
|
Factory 7 : |
Sanwer Road
Factory, Indore 11/12C, Sector E, Sanwer Road, Industrial Area, Indore-452015, Madhya
Pradesh, India |
|
Tel. No.: |
91-731-2723016 / 2723017 |
|
E-Mail : |
DIRECTORS
AS ON 06.09.2011
|
Name : |
Mr. Ayyappan Madhavan Nair |
|
Designation : |
Chairman |
|
Address : |
Sreeprasadam Thamarakulam Lane, Sasthamangalam,
Thiruvananthapuram-695010, Kerala, India
|
|
Date of Birth/Age : |
22.05.1956 |
|
Date of Appointment : |
01.08.2008 |
|
DIN No.: |
00117374 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
1 |
U25193KL1966GOI002621 |
HLL
LIFECARE LIMITED |
Managing
director |
01-08-08 |
20-12-05 |
Active |
NO |
|
2 |
U01119KL1976SGC002799 |
REHABILITATION
PLANTATIONS LIMITED |
Director |
22-09-06 |
22-09-06 |
Active |
NO |
|
3 |
U85110KL2008PTC021819 |
LIFESPRING
HOSPITALS PRIVATE LIMITED |
Director |
18-02-08 |
07-02-08 |
Active |
NO |
|
4 |
U24290KL2012GOI030732 |
HLL
BIOTECH LIMITED |
Director |
12-03-12 |
12-03-12 |
Active |
NO |
|
Name : |
Mr. Suresh Kumar Krishna Panicker Kalampu |
|
Designation : |
Whole Time Director |
|
Address : |
Pranamam T. C. VI/1284/8, Pipeline Road, Thiruvananthapuran-695030,
Kerala, India |
|
Date of Birth/Age : |
29.11.1956 |
|
Date of Appointment : |
19.02.2009 |
|
DIN No.: |
00061232 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
1 |
U25193KL1966GOI002621 |
HLL
LIFECARE LIMITED |
Whole-time
director |
19-02-09 |
19-02-04 |
Active |
NO |
|
2 |
U85110KL2008PTC021819 |
LIFESPRING
HOSPITALS PRIVATE LIMITED |
Director |
07-02-08 |
07-02-08 |
Active |
NO |
|
Name : |
Mr. Rakesh Prasad Khandelwal |
|
Designation : |
Director |
|
Address : |
E-504, Ispatika Apartment, Plot No.27, Sector 4, Dwaraka, New Delhi |
|
Date of Birth/Age : |
03.05.1958 |
|
Date of Appointment : |
12.05.2009 |
|
DIN No.: |
00388355 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Date
of cessation |
Company
Status |
Defaulting
status |
|
1 |
U24211DL1954GOI002377 |
HINDUSTAN
INSECTICIDES LIMITED |
Director |
11-07-05 |
11-07-05 |
11-05-09 |
Active |
NO |
|
2 |
U25193KL1966GOI002621 |
HLL
LIFECARE LIMITED |
Whole-time
director |
12-05-09 |
12-05-09 |
- |
Active |
NO |
|
Name : |
Mr. Manglavil Daivanayakom Sreekumar |
|
Designation : |
Whole Time Director |
|
Address : |
Ragamalika TC 29/1323 (I), Pettah P O, Thiruvananthapuram-695024,
Kerala, India |
|
Date of Birth/Age : |
30.11.1956 |
|
Date of Appointment : |
29.10.2007 |
|
DIN No.: |
01902432 |
|
|
|
|
Name : |
Mr. Sanjiv Kapoor |
|
Designation : |
Director |
|
Address : |
13/397, Civil Lines, Kanpur, Uttar Pradesh, India |
|
Date of Birth/Age : |
04.10.1953 |
|
Date of Appointment : |
03.12.2010 |
|
DIN No.: |
00004005 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Date
of cessation |
Company
Status |
Defaulting
status |
|
1 |
L45200MH1999PLC118949 |
MAHINDRA
LIFESPACE DEVELOPERS LIMITED |
Director |
31-10-03 |
31-10-03 |
- |
Active |
NO |
|
2 |
U65991MH1995PTC155207 |
SAHARA
ASSET MANAGEMENT COMPANY PRIVATE LIMITED |
Director |
25-02-04 |
25-02-04 |
26-04-07 |
Active |
NO |
|
3 |
U92490TN1997PLC037551 |
MAHINDRA
WORLD CITY DEVELOPERS LIMITED |
Director |
22-12-05 |
22-12-05 |
- |
Active |
NO |
|
4 |
U65999UP2000PLC025635 |
SAHARA
INDIA LIFE INSURANCE COMPANY LIMITED |
Director |
10-07-07 |
24-03-07 |
27-06-08 |
Active |
NO |
|
5 |
U67120UP1979PLC004876 |
U.P.
STOCK EXCHANGE LIMITED |
Director |
22-11-08 |
22-11-08 |
- |
Active |
NO |
|
6 |
L99999MH1962PLC012542 |
MAHINDRA
UGINE STEEL COMPANY LIMITED |
Director |
27-07-10 |
28-07-09 |
- |
Active |
NO |
|
7 |
U45200MH2006PLC160730 |
AAMBY
VALLEY LIMITED |
Additional
director |
25-06-10 |
25-06-10 |
07-10-10 |
Active |
NO |
|
8 |
U65921MH1994PTC173469 |
MONEY
MATTERS FINANCIAL SERVICES LIMITED |
Director |
08-09-10 |
10-07-10 |
02-12-10 |
Active |
NO |
|
9 |
U85110MH1997PLC109186 |
SAHARA
INDIA MEDICAL INSTITUTE LIMITED |
Director |
20-09-10 |
14-07-10 |
- |
Active |
NO |
|
10 |
U25193KL1966GOI002621 |
HLL
LIFECARE LIMITED |
Director |
03-12-10 |
03-12-10 |
- |
Active |
NO |
|
11 |
U67200MH1972GOI016133 |
GENERAL
INSURANCE CORPORATION OF INDIA |
Director |
26-09-11 |
26-09-11 |
- |
Active |
NO |
|
Name : |
Ms. Aarti Vij |
|
Designation : |
Director |
|
Address : |
House No. 31, Friends Colony, New Delhi-110065, India |
|
Date of Birth/Age : |
16.11.1963 |
|
Date of Appointment : |
03.12.2010 |
|
DIN No.: |
03413556 |
|
|
|
|
Name : |
Dr. Arun Kumar Panda |
|
Designation : |
Director |
|
Address : |
C-83, Palas Palli, Bhubaneswar, Orissa, India |
|
Date of Birth/Age : |
30.04.1960 |
|
Date of Appointment : |
15.12.2010 |
|
DIN No.: |
00786320 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Date
of cessation |
Company
Status |
Defaulting
status |
|
1 |
U72200OR2008PLC009813 |
ORISSA
E-GOVERNANCE SERVICES LIMITED |
Director |
04-04-08 |
04-04-08 |
10-12-10 |
Active |
NO |
|
2 |
U25193KL1966GOI002621 |
HLL
LIFECARE LIMITED |
Nominee
director |
15-12-10 |
15-12-10 |
- |
Active |
NO |
|
3 |
U24232RJ1978GOI001823 |
RAJASTHAN
DRUGS AND PHARMACEUTICALS LIMITED |
Nominee
director |
19-08-11 |
19-08-11 |
- |
Active |
NO |
KEY EXECUTIVES
|
Name : |
Mr. V. A. Sasidharan Nair |
|
Designation : |
Secretary |
|
Address : |
TC2/1194-1, Saivaram Kedaramnagar, Patom Thituvananthapuram-695004,
Kerala, India |
|
Date of Birth/Age : |
28.05.1952 |
|
Date of Appointment : |
03.04.1997 |
|
PAN No.: |
|
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 06.09.2011
|
Names of Shareholders |
No. of Shares |
|
The President of India, India |
155347 |
|
Naved Masood |
1 |
|
K. Chandramouli |
1 |
|
Dr. A K. Pande |
1 |
|
Total |
155350 |
AS ON 06.09.2011
|
Equity Shares
Break Up |
Percentage |
|
Government |
100.00 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturing, trading and marketing of condoms for National Family Planning programme of Government of India and manufacture of Oral Contraceptives like Birth Control Pills and Intra Uterine devices and health care products like Blood Bags, Hydrocephalus Shuts, Surgical Gloves and Surgical Sutures. |
||||||||
|
|
|
||||||||
|
Products : |
|
PRODUCTION STATUS (AS ON 31.03.2011)
|
Particulars |
Unit |
Installed
Capacity |
Actual
Production |
|
Condom |
MPcs |
1327.85 |
101 |
|
Steroidal OCPs |
Million Cycles |
58.68 |
59 |
|
Non Steroidal OCPs |
Million Tablets |
26.54 |
88 |
|
Blood Bags |
MPcs |
11.50 |
56 |
|
Pregnancy Test Cards |
MPcs |
23.58 |
91 |
GENERAL INFORMATION
|
No. of Employees : |
Not Available |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Bankers : |
State Bank of India, Commercial Branch, Sree Ganesh Kripa, Hotel Jas
Road, Thycaud, Thiruvanathapuram-695014, Kerala, India |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Anathan and Sundaram Chartered Accountant |
|
Address : |
Sivakarthi 123, Sankar Nagar, Neerramankara, Kaimanam,
Trivandrum-695040, Kerala, India |
|
Pan No.: |
AAEFA3563E |
CAPITAL STRUCTURE
AS ON 31.03.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
200000 |
Equity Shares |
Rs.1000/- each |
Rs. 200.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
155350 |
Equity Shares |
Rs.1000/-
each |
Rs. 155.350
Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
155.350 |
155.350 |
155.350 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
1404.250 |
1247.075 |
1124.999 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
1559.600 |
1402.425 |
1280.349 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
1605.979 |
877.172 |
946.917 |
|
|
2] Unsecured Loans |
0.000 |
0.000 |
0.000 |
|
|
TOTAL BORROWING |
1605.979 |
877.172 |
946.917 |
|
|
DEFERRED TAX LIABILITIES |
35.137 |
32.758 |
14.336 |
|
|
|
|
|
|
|
|
TOTAL |
3200.716 |
2312.355 |
2241.602 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
1167.458 |
1224.864 |
728.969 |
|
|
Capital work-in-progress |
158.117 |
23.041 |
354.153 |
|
|
|
|
|
|
|
|
INVESTMENT |
78.542 |
78.542 |
50.670 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
573.931
|
531.200 |
613.051 |
|
|
Sundry Debtors |
1981.451
|
1177.675 |
1323.580 |
|
|
Cash & Bank Balances |
509.295
|
445.723 |
550.447 |
|
|
Other Current Assets |
431.460
|
143.728 |
37.362 |
|
|
Loans & Advances |
444.508
|
298.562 |
305.950 |
|
Total
Current Assets |
3940.645
|
2596.888 |
2830.390 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
834.175
|
609.712 |
578.413 |
|
|
Other Current Liabilities |
1220.406
|
927.308 |
1077.086 |
|
|
Provisions |
89.465
|
73.960 |
67.081 |
|
Total
Current Liabilities |
2144.046
|
1610.980 |
1722.580 |
|
|
Net Current Assets |
1796.599
|
985.908 |
1107.810 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
3200.716 |
2312.355 |
2241.602 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income (Turnover) |
5170.000 |
4400.629 |
3664.186 |
|
|
|
Other Income |
NA |
204.189 |
187.947 |
|
|
|
Exchange Fluctuation |
NA |
49.985 |
(33.304) |
|
|
|
TOTAL (A) |
NA |
4654.803 |
3818.829 |
|
|
|
|
|
|
|
|
Less |
|
|
|
|
|
|
|
|
Material Consumed |
NA |
1114.228 |
1095.302 |
|
|
|
Power and Fuel Charge |
|
198.073 |
193.474 |
|
|
|
Water Charges |
|
14.515 |
9.267 |
|
|
|
Employees Salaries and Benefits |
|
864.544 |
721.690 |
|
|
|
Other Production Expenses |
|
161.876 |
147.190 |
|
|
|
Administrative Expenses |
|
400.965 |
302.291 |
|
|
|
Marketing Expenses |
|
466.305 |
363.197 |
|
|
|
Insurance Charge |
|
6.630 |
5.391 |
|
|
|
Value of finished goods purchases – trading |
|
869.136 |
737.768 |
|
|
|
Contract Expenses |
|
7.646 |
0.000 |
|
|
|
Pay Revision Arrears |
|
51.963 |
50.468 |
|
|
|
(Increase) / Decrease in Stock |
|
72.379 |
(158.164) |
|
|
|
Prior Period Adjustments |
|
(3.109) |
3.489 |
|
|
|
TOTAL (B) |
NA |
4225.151 |
3471.363 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
NA |
429.652 |
347.466 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
NA |
75.605 |
92.064 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
NA |
354.047 |
255.402 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
NA |
127.907 |
89.959 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
NA |
226.140 |
165.443 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
NA |
76.801 |
89.661 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
184.300 |
149.339 |
75.782 |
|
|
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
|
|
Transfer to General Reserve |
NA |
122.076 |
57.607 |
|
|
|
Dividend |
NA |
23.303 |
15.535 |
|
|
|
Tax on Dividend |
NA |
3.960 |
2.640 |
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Export Earnings / Samples |
NA |
518.166 |
190.560 |
|
|
|
Freight and Insurance |
NA |
10.925 |
9.139 |
|
|
TOTAL EARNINGS |
NA |
529.091 |
199.699 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
NA |
31.515 |
41.464 |
|
|
|
Stores & Spares |
NA |
39.699 |
12.006 |
|
|
|
Capital Goods |
NA |
195.427 |
46.680 |
|
|
TOTAL IMPORTS |
NA |
266.641 |
100.150 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
1186.35 |
961 |
-- |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
PAT / Total Income |
(%) |
NA
|
3.21 |
1.98 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
NA
|
5.14 |
4.52 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
NA
|
5.92 |
4.65 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
NA
|
0.16 |
0.13 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
2.43
|
1.80 |
2.10 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.84
|
1.61 |
1.64 |
LOCAL AGENCY FURTHER INFORMATION
FINANCIAL PERFORMANCE
The company has
achieved a turnover of Rs. 5170.000 Millions, a growth of 17 % compared to the previous
year’s turnover of Rs. 4420.000 Millions. The company has earned a net profit
of Rs. 184.300 Millions compared to Rs. 149.300 Millions during the previous
year.
Considering the
value of transactions handled by the Procurement and Consultancy Division and
Infrastructure Division, the company handled a business of Rs. 11310.000
Millions compared to Rs. 12940.000 Millions during the previous year.
JOINT VENTURE COMPANY
LifeSpring
Hospitals Private Limited – the 50:50 joint venture company formed by HLL and
Acumen Fund Inc., USA added six more hospitals at Kukatpally, Amberpet, Alwal,
Champapet, Puranapool and ToliChowki in Hyderabad. With this addition of
hospitals, the company has 12 hospitals in and around Hyderabad. The company
had closed down business operations of hospitals in coastal districts of
Vijayawada, Nellore and Rajahmundry. These hospitals were closed down for the
strategic reason that for LifeSpring Hospitals, cluster approach would work
better than dispersed approach. The company is establishing another cluster of
hospitals in National Capital Region New Delhi.
During the year,
the joint venture company posted a gross income of Rs. 53.000 Millions compared
to Rs. 34.500 Millions during the previous year. During the year, the business
income of the company had grown by 74% as compared to business income for year
2009-10. The measures taken by the company to drive efficiency has yielded
considerable results. The company’s loss before tax (Rs. 46.700 Millions) has
decreased by a heartening 40% as compared to corresponding figure (Rs. 28.000
Millions.) during the previous year.
Future outlook of
the joint venture company is promising and hence it plans to scale-up business
in the next five years. The company plans to expand to urban localities
pan-India, based on expansion criteria namely attractive market and ability to
serve. The business plan 2011-15 envisages setting up 100 hospitals including
existing 12 hospitals.
AWARDS AND RECOGNITIONS
The company
received the following awards and recognitions.
Peroorkada Factory, Trivandrum
Central Ministry
of Labour DGFASLI Award - 1st Prize to PFT for best safety performance for 2008
(declared in 2010)
Indira Gandhi Raja
Bhasha Award for best performance of Official Language Policy (2009-10)
GREENTECH Award
2009 for best Environmental Performance and 2010 in Gold Star category for
effective excellence in Environment Management System.
Awards from Kerala State Factories and Boilers 2010
·
Best safety committee.
·
Second best safety performance.
Awards from National Safety Council (Kerala
Chapter) 2010
·
Best safety performance.
·
Best safety officer
·
Best safety story
Kerala State
Pollution Control Board Excellence Award 2011 in large scale sector
Akkulam Factory, Trivandrum
Received the
Kerala State Pollution Control Board Award for Substantial and Sustained
Pollution Control, securing third prize among small scale industries and also
received a cash award of Rs. 0.025 Million in the year 2011.
Secured third
prize for case study presentation on elimination of feed wastage of IUD Copper
T model 380-A., from IEEE - Kerala chapter in
March 2011.
Export Awards:
The Company won
AIRIA Latex Export Award for 2009-10 and Capexil Special Export Award for
2009-10.
MANAGEMENT’S DISCUSSION AND ANALYSIS
OVERVIEW
Manufacturing capability
Subject is a
leading manufacturer and marketer of a range of Contraceptive products around
the globe. It also provides a variety of hospital products, pharma products and
healthcare delivery services.
The company has capacity
to manufacture 1.316 billion Condoms at Peroorkada Factory, Thiruvananthapuram
and Kanagala Factory, Belgaum which account for nearly 10 percent of the global
production capacity.
The union budget
for the health sector witnessed a quantum jump from Rs. 80000.000 Millions in
2004-05 to Rs. 210000.000 Millions in 2009-10. Spending by the State
Governments on health care also witnessed a similar increase. As Subject
products and services predominantly cater to state-sponsored healthcare
projects, the increased spending in this sector by the Central and State
Governments have provided huge opportunities for the company to expand its
business.
Corporate Plan – 2010:
The company
conceptualized the Corporate Plan-2010 in year 2003. The Plan was implemented
over the last 7 years. As envisaged in the plan, Subject strengthened its core
capabilities and diversified into the services domain.
Subject expanded
its manufacturing capacity for Condoms (from 1034 M.Pcs. to 1316 M.Pcs.) and
Blood Bags (from 5.0 M Pcs to 11.5 MPcs), thereby maintaining its leadership
position in these product categories. The company also established two new
manufacturing facilities, one for Female Condoms at Kochi and the other for
Pharmaceutical products (leased facility) at Indore. Besides, the company is
currently in the process of further expanding its Condom manufacturing capacity
at Peroorkada Factory, Thiruvananthapuram by 180 M. Pcs, thus taking the total
condom production capacity of Subject to 1496 M. Pcs.
The company has ventured
into the healthcare services domain through its Diagnostic Services,
Procurement and Infrastructure Development Divisions based in New Delhi.
LifeSpring
Hospitals (Private) Limited, a joint venture company established with the
mission to be the foremost healthcare provider - to deliver high-quality,
affordable core maternal healthcare to low income mothers, has entered its
fourth year of service.
Subject has
commenced business in all broad business verticals mentioned in the Vision 2010
document except contract research.
Now, the company
has engaged a consultant to frame Vision 2020, taking into account
recently-commenced businesses and for further diversification, while
strengthening its core segments namely Contraceptives and Hospital products. The
objective of Vision 2020 is to make Subject a Rs. 100000.000 Millions
healthcare company.
Strategic Business Units:
Consequent to the
expansion/diversification of the company’s business, Subject faced various challenges
in managing a diversified businesses portfolio. To meet this challenge, the
company restructured its business operations into three independent Strategic
Business Units (SBUs).
With a view to
bring in more accountability, efficiency and operational autonomy, the
structuring of SBUs are as under. Sl. No. Strategic Business Units (SBU)
1. Contraceptives
and Pharmaceuticals SBU
2. Hospital
Products SBU
3. Services SBU
Contraceptives and Pharmaceuticals:
The Contraceptives
and Pharmaceuticals SBU manufacture and market a range of Contraceptive and
Pharmaceutical products. The range includes Male Condoms, Female Condoms,
Intra-Uterine Devices, Oral Contraceptive Pills – both Steroidal and
Non-steroidal, Emergency Contraceptive pills, Tubal rings and Injectables. The
SBU also offers a whole range of Healthcare products for women that address
their social, mental and physical well being. The product basket includes -
Contraceptives, Ovulation Inducers, Antiemetics, Menstrual cycle regulators,
Antifibrinolytics, MTP pills, Pregnancy test kits, Natural products and
Vaccines.
Hospital Products:
Hospital products
SBU offers a wide range of critical hospital products and services to
healthcare professionals in the field of transfusion services and advanced
patient care. The product range includes Blood Collection Bags, Surgical
Sutures, Hydrocephalus shunts, Tissue Expanders, Surgical and Examination
Gloves, Blood Transfusion sets, Intravenous Sets and Blood Banking Equipments.
International Business Division (IBD)
The company’s
International Business Division (IBD) distributes products to over 90 countries
worldwide. MOODS, the flagship consumer brand of condoms is marketed in 42
countries and HL- Haemopack Blood Bags in 20 countries. MOODS is now one among
the top four Condom brands in UAE.
Since inception,
tenders and institutional sales have been the major sources of revenue for the
International Business Division. To achieve a quantum leap in international
business, the company plans to focus more on branded business with special
emphasis on Condoms and Blood Bags. The thrust areas of Subject international
business operations are South America, South East Asia, Middle East and Africa,
European Union and Commonwealth Independent States and Russia. Subject has
invested in registering its brands in these countries. In 2011-12, the company
plans to tap new markets in countries in these regions.
Subject has in
place its marketing executives in the Gulf Cooperation Council (GCC) countries,
Brazil, Kenya and Bangladesh to ramp up marketing of company’s products in
these territories.
The company won
AIRIA latex export award for 2009-10 and CAPEXIL special export award for the
year 2009-10.
HI-Care Division (HCD)
During the year, HI-Care
Division (HCD) launched a new blood bag variant under the brand name Donato
(signifies “Gift of God”) at Mumbai on October 31, 2010. Donato Blood Bags are
feature-rich with Needle injury protector, frosted tubing’s, inline sampling,
vaccutainer port, LD filter and designed to meet the needs of advanced
transfusion service requirements in the country. These in built features will
enable ease of use and convenience to end users - both donors as well as
medical professionals.
During the year,
the division had set up 32 blood storage centers in 14 districts in Kerala,
meeting the guidelines of NACO and NRHM. The division also received contracts
to set up blood component separation units and neonatal care units in Kerala.
Women’s Healthcare Division (WHD)
The company’s WHD
now offers 30 products with a pan-India presence. The leading brands of WHD are
Novex DS, Hilgestrone and Hilrab.
WHD operates in
the Gynecology segment of Indian Pharma Market - valued at Rs. 26850.000
Millions, with an annual growth of 15%. The division has 60% coverage in the
segment, of which high priority product groups would be Dysfunctional Uterine
Bleeding (DUB), Iron and Folic acid, Intra Uterine Contraceptive Devices
(IUCD)s and Galactagogue.
Consumer Business Division (CBD)
Moods brand of
condoms owned by the company is available in 19 variants and was selected as a
“Super Brand”. The brand also obtained the coveted “Power Brand” status. Moods
is the only condom brand to be conferred this honour.
Service Divisions
Subject has three
service divisions; these are:
Procurement and Consultancy Division (PCD)
Procurement and
Consultancy Services Division set up in 1998, is one of the designated National
Procurement Support Agencies (NPSA) under the Ministry of Health and Family
Welfare for domestic procurement.
PCD is the
implementation partner of SAARC Secretariat for procurement and supply of
Medical Equipments to SAARC member countries.
Infrastructure Development Division (IDD)
The company
completed up gradation of Bangalore Medical College and Salem Medical College
Project under PMSSY 1st Phase in July 2010 and August 2010 respectively.
During the year,
the Thiruvananthapuram Medical College (TMC) Up gradation Project was inaugurated
on January 5, 2011 by the Honourable Union Minister for Health and Family
Welfare. The Salem Medical College Up gradation Project was inaugurated on
August 20, 2010 by the Chief Minister of Tamil Nadu. Subject has also completed
the up gradation of the Bangalore Medical College.
MoHFW has
entrusted Subject the task of upgrading three more medical colleges, apart from
construction of National Institute of Para-medical Sciences (NIPS) and Regional
Institute of Para-medical Sciences (RIPS).
Diagnostic Services Division:
“Hindlabs” set up
by Subject, in partnership with Employees State Insurance Corporation (ESIC),
is providing facility management services for management and operations of CT /
MRI centres at ESIC Model Hospitals at Andheri (East), Mumbai and Rajajinagar,
Bengaluru. The maintenance and upkeep of the 64 Slice CT scan machine and 1.5
Tesla MRI scan machine are coordinated by Subject team.
The division is
expanding the “Hindlabs” chain by setting up collection centres and new laboratory
networks for CGHS and other central institutions.
Lifecare Centre:
This division, in
partnership with Government of Kerala, is setting up a specialty retail centre
called Lifecare Centre at Medical College, Thiruvananthapuram. Lifecare centre
will focus on providing surgical implants, consumables and life-saving drugs.
The mission of the centre is to provide these products at an affordable price
than the market price. This is to ensure much-needed relief to poor patients.
Lifecare Centre
project is planned to be extended to other four medical colleges in Kerala and
to the Regional Institute of Ophthalmology, Thiruvananthapuram.
FORM 8
|
Corporate
identity number of the company |
U25193KL1966GOI002621 |
|
Name of the
company |
HLL LIFECARE LIMITED |
|
Address of the
registered office or of the principal place of business in |
Hill Bhavan, Mahilamandiram Road, Poojapura P. O., Thiruvananathapuram–695012, Kerala, India |
|
This form is for |
Modification of
charge |
|
Type of charge |
Immovable
property Book debts Movable property
(not being pledge) |
|
Particular of
charge holder |
State Bank of India, Commercial Branch, Sree Ganesh Kripa, Hotel Jas
Road, Thycaud, Thiruvanathapuram-695014, Kerala, India |
|
Nature of
instrument creating charge |
Supplemental
Agreement of Hypothecation of Movable assets and Current Assets for increase
in the overall limit |
|
Date of
instrument Creating the charge |
28.09.2011 |
|
Amount secured by
the charge |
Rs. 4135.900 Millions
|
|
Brief of the
principal terms an conditions and extent and operation of the charge |
Rate of interest Cash Credit
- 250 bps above base rate , Term Loan
1 - 300 bps above base rate , Term Loan II and III - 550 bps above 6 months LIBOR , Term Loan IV , V ,VI ,VII,
VIII, IX - 300 bps above base rate Terms of repayment Terms of
repayment Margin Raw Materials -
25 % Stock In Process
-35 % Finished Goods -
25 % Book Debts - 25 % Letter of Credit
- 10 % Bank Guarantee -
10 % Term Loan - ( Rs
573.000 Millions ) - 28 % Term Loan -
Existing - 25 % Extent and operation of the charge Aggregate Credit
Limit enhanced to Rs 4135.900 millions. Term Loans
aggregating to Rs. 909.000 millions.; Cash Credit Rs 1000.000 millions; Bank
Guarantee Rs 1000.00 millions, Letter of Credit Rs 1200.000 millions, Credit
Exposure --Rs 23.100 millions, Forward Contract Rs 3.800 millions Charge over
company's assets |
|
Short particulars
of the property charged (Including location of the property) |
Cash Credit –
1000.000 Millions -Hypothecation over the entire current assets of the
company including stocks, receivables etc Bank Guarantee -1000.000 Millions
-Counter Guarantee and Charge over the current assets Letter of
Credit 1200.000 Millions Charge over
the merchandise under the letter of credit Term Loan of Rs
26.000 Millions - Charge over the machinery purchased Term Loan of Rs
150.000 Millions - Charge over the machinery purchased on Akkulam Factory Term Loan of Rs
160.000 Millions - Charge over the machinery purchased in Peroorkada factory. Term Loan of Rs
60.000 Millions for Office space in Noida - Equitable Mortgage over the lease
hold rights over 5000sqft of land and proposed building. Term Loan of Rs
290.000 Millions for steroidal and ARV plant in Kanagala - Equitable Mortgage
over 15.33 acres land and proposed building and machinery. Term Loan of
150.000 Millions for MRI Machines - Charge over the machinery purchased out
of Bank Finance. Term Loan of
40.000 Millions for packing facility in CEZ Kochi - Charge over the machinery purchased out of
Bank Finance. Term Loan of
33.000 Millions for establishment of Hind labs in New Delhi - Charge over the
Medical Equipments. Collateral EM of 106.447
cents of land with building in the name of HLL at Poojappura |
|
Charge
identification number of the charge to be modified |
90016152 |
|
Particulars of
the present modification |
Overall credit
limit enhanced to Rs 4135.900 Millions with the following sub limits: 1) Cash Credit
-1000.000 Millions 2) Term Loan 1 –
26.000 Millions 3) Term Loan-II
-120.000 Millions 4) Term Loan III
– 40.000 Millions 5) Term Loan IV
-150.000 Millions 6) Term Loan V –
60.000 Millions 7) Term Loan VI
-290.000 Millions 8) Term Loan VII
-150.000 Millions 9) Term Loan VIII
-40.000 Millions 10) Term Loan IX
-33.000 Millions 11) Letter of
Credit-1200.000 Millions 12 Bank Guarantee
-1000.000 Millions 13) Credit
Exposure-Export -11.000 Millions 14) Import
-12.100 Millions 15) ForwardContract-3.800
Millions |
FIXED
ASSETS
v Land
v Building
v Plant and Machinery
v Furniture and Fixture
v Motor Vehicles
WEBSITE DETAILS
PROFILE
Subject commenced
its journey to serve the Nation in the area of healthcare, on 1st
March 1966, with its incorporation as a corporate entity under the Ministry
of Health and Family Welfare, Government of India. Subject was set up in the
natural rubber rich state of Kerala, for the production of male contraceptive
sheaths for the National Family Welfare Programme. Subject commenced commercial
operations on 5th April 1969 at Peroorkada in Thiruvananthapuram (formerly
Trivandrum). The Plant was established in technical collaboration with M/s
Okamoto Industries Inc. Japan.
Two most modern
Plants were added, one at Thiruvananthapuram and the other at Belgaum in
1985. Another Plant was added in the early nineties at Aakkulam in
Thiruvananthapuram for the production of Blood Transfusion Bags, Copper T
IUD’s, Surgical Sutures and Hydrocephalus Shunt.
Subject has grown
today into a multi-product, multi-unit organization addressing various
public health challenges facing humanity.
Subject had set
its sights in 2003 - when it had a turnover of a mere Rs 1630.000 Millions - to
be a Rs 10000.00 Millions company by the year 2010. On the path of rapid
growth, this year (2010) it has not only surpassed this figure but has drawn a
clear road map to achieve a five fold growth by the year 2015.
Subject is today a
Mini Ratna and upgraded as a Schedule B Central Public Sector
Enterprise.
Subject is the
only company in the world manufacturing and marketing the widest range of
Contraceptives. It is unique in providing a range of Condoms, including
Female Condoms, Intra Uterine Devices, Oral Contraceptive Pills - steroidal,
non-steroidal and Emergency contraceptive pills; and Tubal Rings. Millions
produces today 1.316 billion condoms annually making it one of the
world’s leading manufacturers of condoms, accounting for nearly 10 percent
of the global production capacity.
Subject Health
care product range include: Blood Collection Bags, Surgical Sutures, Auto
Disable Syringes, Vaccines, In - Vitro Diagnostic Test Kits, Pharma products
for Women, Natural products, Hydrocephalus Shunt, Tissue Expanders, Surgical
and Examination Gloves, Blood Banking equipment, Neonatal equipment, Blood
Transfusion and Intravenous sets, Vending Machines, Iron and Folic Acid
Tablets, Sanitary Napkins, Oral Rehydration Salts and Medicated Plasters.
Subject Blood Bags
were launched in Brazil in 2006. Subject also launched its non-steroidal
contraceptive pill under the brand name Ivyfemme in Peru in October 2008.
Subject has
introduced Closed System Blood Bags that are integrated with Leukocyte Filter -
called LD Bags. These bags are intended for leuko-depletion immediately upon
collection of blood from donors at blood banks.
In collaboration
with The Female Health Company (FHC), of US, Subject is marketing FC female
condom in India. The female condom is the only female controlled prevention
technology approved by the US FDA and the WHO. Subject launched the nitrile
female condom - Velvet in India in December 2007. Targeted at
contemporary Indian women and new age couples, nitrile condoms empower women
providing dual protection against unwanted pregnancy and STDs, HIV/AIDS
Subject has also
launched several initiatives in the services sector – for medical
infrastructure development, diagnostic centres and procurement consultancy.
These have been conceived to bring about a whole new realm of accessible,
affordable healthcare delivery to every citizen.
Over the years
each of the initiatives taken up by Subject are targeted at reaching quality
healthcare at the doorstep of every family. Associate Institutions of Subject
namely HLFPPT and LifeSpring Hospitals have ensured this to the
nation’s underserved and vulnerable populace, at an affordable cost.
With a vast array
of innovative products and social programmes to meet the nation’s health care
needs Subject is firmly on track, with its vision of Innovating for Healthy
Generations.
Subject achieved a
turnover of Rs. 4420 million during 2009-10, registering a growth of 20% over
that for 2008-09 of Rs.3680 million. However the business handled by the
company totaled Rs. 12960 million, including the value of transactions handled
by its Procurement and Consultancy Division of Rs. 4860 million and
Infrastructure Development Division of Rs 3690 million.
Manufacturing
Facilities
Subject has today six
state of the art manufacturing facilities. Subject commenced its
commercial operations on April 5, 1969 at Peroorkada in Thiruvananthapuram in
the state of Kerala. Together with the manufacturing facility at Peroorkada,
Subject today has five state-of-the-art manufacturing facilities at: Kanagala
near Belgaum (1985) - for contraceptives and pharmaceutical products;
Akkulam in Thiruvananthapuram (1994) - for hospital products; Kakkanad
in the Cochin Special Economic Zone (2004) - for female condoms and male
condoms for export; and Manesar in Gurgaon (2007) - for rapid in-vitro
diagnostic test kits. All these units have ISO 9001, ISO 14001- quality and
environmental management system certifications. Subject Peroorkada, Akkulam and
Kanagala Plants have OHSAS 18001 Certification for efficient occupational
health and safety management system. The testing laboratory for finished
products at Peroorkada factory has NABL accreditation under ISO/EC 17025.
Peroorkada
Facility, Thiruvananthapuram ( PFT ): The manufacturing unit at Peroorkada was set
up in 1969 in technical collaboration with M/s Okamoto Industries Inc. Japan.
The plant has since undergone continuous modernisation over the years and has
an annual production capacity of 1066 million pieces of condoms. The facility
is equipped with modern machines and equipment for production, inspection and
quality testing, conforming to GMP and meets international standards. The unit
produces many variants of condoms with different flavours and textures. Condoms
manufactured in this facility have product certifications such as, CE, KITE,
SABS, NF Mark, and meet a range of international quality specifications and
standards such as: WHO 2003, ISO 4074:2002, SANS ISO 4074, ASTM D 3492, and
GOST- 4645-81. The facility has certifications under ISO 9001, ISO 13485, WHO
GMP, OHSAS and ISO 14001.
Akkulam Facility,
Thiruvananthapuram ( AFT ): AFT is a modern state-of-the-art facility for
manufacture of Blood Bags and other medical devices namely IUDs (Intra Uterine
Devices), Surgical Sutures, Hydrocephalus Shunts, Tissue Expanders and Tubal
Rings.
The manufacturing
facility is centrally air - conditioned and has class 10000 and class 100 clean
areas. The facility is certified for conformity with ISO 9001, WHO GMP, ISO
13485, OHSAS 18001 and ISO 14001.
The annual production
from this unit is: Blood Bags – 11.5 million pieces, Copper IUD - 5.5 million
pieces, Shunts -5,000 pieces, Tissue Expander - 2000 pieces, Surgical sutures –
1,25,000 dozens and Tubal Ring – 2.5 million pairs. The products from this unit
carry the CE Mark.
Kanagala Facility,
Belgaum ( KFB ): The Kanagala plant in Belgaum, Karnataka commenced its operation with
production of condoms in 1985 using Japanese technology. This unit underwent
diversification in 1992 with the tabletting facility for birth control pills -
Mala-D/N and the formulation and tabletting of Saheli (centchroman) the
indigenous, non-steroidal once-a-week pill. The tabletting of Emergency
Contraceptive pills was started in 2003. Manufacturing facility for centchroman
bulkdrug was added in 2004. In 2006, commercial manufacturing of women
healthcare products was commenced. The manufacturing unit has GMP as well as
ISO 9001, ISO 13485, ISO 14001 and OHSAS 18001 certifications.
Kakkanad Facility,
Cochin ( KFC ): Subject female condom manufacturing facility at Cochin Special Economic
Zone, Kakkanad, has been set up in technical collaboration with M/s. Female
Health Company (FHC), US. The female condom manufactured at KFC is the second
generation of female condoms made from synthetic nitrile latex, the product
generically being termed FC2. The installed capacity of the plant is 7 million
pcs of FC2 per year. In addition, KFC has a fully automatic testing and packing
facility for male condoms with an annual capacity of 150 mln. pcs per year. This
facility mainly caters to the export market. KFC has the ISO 9001:2000, ISO
13485 and WHO GMP certification for manufacturing and sale of female condoms
(FC2).
Manesar Facility,
Gurgaon( MFG ): Subject in-vitro
immuno diagnostics kit manufacturing facility at Manesar, Gurgaon, Haryana has
an installed capacity to manufacture 26 million rapid pregnancy test kits per
year on single shift operation. The unit commenced its operations in November
2007. The unit manufactures rapid test kits for detection of metabolic hormones
such as human chorionic gonadotropin (hCG) in urine and prognosis of diseases
such as dengue, malaria(different strains), kala-a-zar (leishmaniasis), TB,
chikungunya and other infectious diseases.
Indore Facility,
Indore (MFI): Subject Indore facility commenced operation in April 2010 in the
Industrial area in the commercial capital of MP. The Plant is a formulation
facility for the production of a range of pharma products including Tablets,
Capsules and ORS.
Global Outlook
With the changing
socio-political climate, global health programmes are constantly seeking
diverse solutions in the area of medicine and healthcare. Subject provides the
perfect answer to many questions that the world faces in healthcare, thanks to
its extensive experience, innovative technologies and ample resources. The
innovative products and services of Subject today reach over 115 countries
spanning the seven continents. Its consultancy services and products are part
of the global healthcare packages of international agencies such as UNPFA,
UNOPS, UNHCR, WHO, PSI and IDA.
Marketing
Over the past two
decades, Subject has steadily set up a strong and sound infrastructure for direct
marketing. Subject has put in place a vast distribution network covering
the length and breadth of the country. Subject products today reach over 200000
retail outlets, covering 3500 hospitals, reaching over 30000 medical
professionals, with over 2800 stock points, has over 700 frontline team
members placed in every town, with offices in all metros and mini metros, and
reaching over one lakh villages in the remotest corners of the nation.
It is the leading social
marketing organization in the country in the area of contraceptives - with
a market share of over 65 percent in the rural and semi urban markets,
including in the highly populated states of UP, Madhya Pradesh, Bihar etc.
Subject has made
vast inroads in the commercial segment too, with the growth in its market share
from 0.1 percent in the nineties to 15 percent at present. Subject products are
today exported to over 115 countries.
New Business Areas
Subject has
ventured into the area of Vaccines – to take on the challenge posed by
communicable diseases, which are responsible for a significant share of the global
burden of diseases, particularly in developing nations. The need to have
affordable high quality vaccines for preventing communicable diseases is a
public health priority in India particularly for the underprivileged sections
of society. With this objective in view, Subject introduced – Hivac – B: a
recombinant vaccine for Hepatitis B and Tyfex: a highly purified VI Capsular
Polysccharide vaccine for Typhoid, and recently Hilrab – the human rabies
vaccine.
The Ministry of
Health and Family Welfare handed over to Subject in 2008, 430 acres of land at
Chengalpet, near Chennai in Tamil Nadu, for its proposed Integrated Vaccine
Project - a project of national importance and the MediPark - an
exclusive industrial park for the development of medical technology products
and the Auto-Disable Syringe plant. Innovative technologies, expertise and
highly qualified and skilled manpower are the main pillars, which enable
Subject to offer perfect solutions to many problems that the world faces in
healthcare.
Subject started
the LifeSpring Hospital Chain as an initiative for creating access to
good quality and affordable maternal and child care, for the low income
population. The first LifeSpring Hospital was launched at Hyderabad in December
2005 and also at Kanpur and at Agra in UP.
Subject and Acumen
Fund, a nonprofit venture philanthropy fund based in the US formed on 18th
March, 2008, LifeSpring Hospitals (Private) Limited - a joint venture intended
to create a chain of small hospitals (20-25 beds) focused on providing
low-income clients in the country, widespread access to maternal and child
health care services. The company, a 50/50 equity partnership between Subject
and Acumen, has already opened five hospitals in 2008 and plans to open thirty
across India by the end of 2010 and scale to 140 franchised hospitals between
2010 and 2012. This is a unique social franchising LifeSpring charges range
between 30-50% of the prevailing market rates, and will significantly reduce
the burden of rising health costs on the nation’s low-income communities,
helping to reduce poverty. LifeSpring Hospitals offers the following key
services: antenatal care, postnatal care, deliveries (normal and caesarean), family
planning services and medical termination of pregnancy, pediatric care,
including immunizations, as well as diagnostic services, a pharmacy, and health
care education to the communities in which it works
Infrastructure
Development Division of Subject is a premier consultancy organisation
for development of medical and allied infrastructure facilities. Medical
infrastructure projects being executed by Subject include the upgradation of
Medical Colleges at Thiruvananthapuram, Bangalore, Salem, Madurai, Rohtak,
Nagpur and Aligarh under the Pradhana Mantri Swasthya Suraksha Yojana (PMSSY).
Also, Subject is upgrading the JIPMER Institute at Puducherry and is the
in-house consultant to Government of India for setting up six AIIMS - like
institutes at Bhopal, Bhubaneshwar, Jodhpur, Patna, Raipur and Rishikesh. The
medical infrastructure development projects handled by Subject today totals
over Rs. 45000 million ($1000 million).
HLL Procurement
and consultancy services Division provides consultancy services to Government
of India, State Governments and other institutions for procuring a range of
healthcare and hospital products, equipment and services. It is designated as a
National Procurement Support Agency (NPSA). With a team of highly qualified and
experienced professionals, it has proven expertise to undertake consultancy
assignments including bid process management, procurement of goods and stores,
as well as project planning and monitoring. Procurement and Consultancy
Services Division has ISO 9001 Certification.
Hindlabs, a novel
initiative delivers high-end diagnostic services adding value to partner
hospitals by deploying the latest diagnostic technology and operational
support. The objective is to deliver quality services at affordable costs for
the common people. Hindlabs provides professional lab management services for
both in-vitro diagnostics and radio diagnosis centres in hospitals. Subject has
set up a most modern diagnostic center at the CGHS Dispensary at New Delhi and
is also operating three 1.5 Tesla MRI Scan Centres at the Thrissur, Alapuzha
and Kottayam Medical Colleges in Kerala.
A whole range of women
healthcare products have been introduced by Subject Women Healthcare
Division (WHD), with a promise to provide total healthcare for women of all
ages - addressing their social, mental and physical well being. WHD’s product
basket includes - Contraceptives, Ovulation Inducers, Antiemetics, Menstrual
Cycle Regulators, Antifibrinolytics, MTP Pills, Pregnancy Test Kits, Natural
Products and Vaccines. It has a strong distribution network, reaching out to
over 13000 gynaecologists across the country.
Subject has
forayed into Natural Products for human wellness, in the area of women
healthcare, health generics, symptomatic relief, neutraceuticals and personal
healthcare, in the Indian market. At present H Subject is partnering with the
renowned ayurvedic institution of Kerala – Kottakkal Arya Vaidya Sala (AVS), to
introduce a range of ayurvedic products in the domestic and international
markets. Subject has since introduced – Lactohil – an ayurvedic galactagogue
that also serves a s health tonic for lactating mothers and Herbs and Berries –
Chyavanules – Chyawanaprash in granular form.
Subject has
commenced manufacture and distribution of ‘Nishchay’ Rapid Diagnostic Test
kits for the detection of Pregnancy in markets all over the country,
from its manufacturing facility at Manesar in Haryana. Subject plans to
introduce in the near future Diagnostic kits for the detection of Malaria and
Dengue fever and Chikungunya. The overall objective is to effectively bring
down the infant/maternity mortality rate, and Malaria and Dengue mortality
reduction.
ORIGIN AND HISTORY
To
trace briefly, HLL’s ‘Milestones’ in the 44th year since its formation:
01March 1966
• Incorporated
as a company under the Ministry of Health and Family Welfare of the Government
of India.
05 April 1969
• Commences
commercial production of Condoms at its Peroorkada Factory
Thiruvananthapuram (PFT). Production capacity – 144 million pieces a
year.
1976
• Production
capacity doubled to 288 million pieces a year with the addition of two
more lines in the moulding section.
1985
• Addition
of a new plant at Thiruvananthapuram with the latest state-of-art Japanese
Technology. Commencement of new condom plant at Kanagala, Belgaum (KFB). Raises
HLL’s total Condom production capacity to 800 million
pieces a year.
1991
• HLL
recognized as a MOU signing CPSU by the Government of India.
• HLL
granted the 510(k) Registration by the Food and Drug Administration (FDA) US,
for its Male Condoms.
1992
• Adds
manufacture of Medigard Surgical & Examination Gloves at PFT.
• Commences
formulation and tabletting of Saheli (Centchroman) once-a-week non-
steroidal pill at the Kanagala plant near Belgaum (KFB).
1993
• Plant
for formulation and tabletting of Mala-D Oral pills, commissioned
at KFB.
1994
• Commences
production of copper-T Intra-Uterine Device (IUD) at its Aakkulam
Factory, Thiruvananthapuram (AFT).
• Commences
commercial production of Ceredrain Hydrocephalus Shunts.
1995
• Introduces
Surgical, Synthetic and Catgut Sutures.
• Commences
manufacture of HL-Haemopack blood tansfusion bags at AFT.
• HLL
awarded NF mark.
1996
• HLL
awarded ISO 9002 certification - for PFT (Condom manufacture) and AFT
(manufacture of blood bag, copper-T and hydrocephalus shunt.
1997
• HLL,
the first company from India selected by the World Health Organisation (WHO)
for sourcing of Condoms.
1998
• HLL
Peroorkada plant (PFT) awarded CE mark
• HLL’s
Akkulam plant (AFT) awarded the CE mark.
• Hindustan
Latex Family Planning Promotion Trust (HLFPPT) a not-for-profit
organisation of HLL commences several social marketing projects and services in
different parts of the country.
2000
• Receives
MOU award and Certificate of merit from the Vice President of India, for
achievement of MOU targets.
• AFT
awarded ISO 14001 certification.
2002
• PFT
and KFB awarded ISO 14001 certification.
• KFB
awarded the CE mark for Condoms.
• Introduces
HL HAEMOSAFE Instant Needle and Syringe Destroyer, for destroying used
needles.
2003
• Receives
MOU Award from the President of India, for excellence in the
achievement of MOU targets for 2001-2002, on 5th April 2003.
• Achieves
a turnover of Rs. 1500.000 Millions.
• Introduces
‘Preventol’ Emergency Contraceptive Pills.
• Introduces
for Blood Bank automation, HiCare Blood Collection Monitor and HiCare
Tube Sealer for sealing Blood Bags.
• HLL
commences manufacture of Tissue Expanders at AFT.
• HLL
exports touched Rs.13 Crores, to over 60 countries around the world.
• HLL
emerges as the nation’s top social marketing organisation in the area of
contraceptives.
• Commercial
production of Surgical Sutures launched at AFT by the Union Minister for
Health and Family Welfare on 27th September.
2004
• Launches
Moods condoms in the Middle East on 22nd January.
• HLL’s
Female Condom launched by the Secretary, Department of Family Welfare at
New Delhi on February 13.
• Launches
Sanitary Napkins “Sakhi” at Indore on 29thFebruary.
• Cochin
Special Economic Zone (CSEZ) unit inaugurated on 4th March.
• Records
a turnover of Rs. 1625.400 Millions.
• Receives
Government of India’s MOU Award from the Prime Minister of India,
on being adjudged amongst the top ten Of the Central Public Sector Units, on
the basis of MOU targets achieved, on 4th September.
• Launched
‘Autolok’ Auto destructive syringes, at New Delhi on 16th
December.
2005
• Contributes
Rs 20 lakhs to the Prime Ministers Relief Fund.
• Condom
Vending Machines installed in Kerala by HLFPPT on 29th July.
• HLL
launches Moods variant - Spiral Condoms, at Hyderabad on 7th August.
• Receives
the National Safety Innovation Award from the Ministry of Labour
Government of India, on 17th September.
• PFT
awarded the OHSAS 18001 Certification on 25th September.
• Receives
from the Union Finance Minister Capexil’s Export Award for outanding export
performance on 28th November.
• HLL
launches Moods Glow Condoms at a special function at Thiruvananthapuram
on 1st December.
• The
first LifeSpring Hospital at Moula Ali, a suburb near Hyderabad,
inaugurated by the Union Secretary for Health and Family Welfare, on 10th
December.
2006
•
Women’s Health Care Pharma Products launched by the Union Secretary for
Health and Family Welfare at Thiruvananthapuram on 13th January.
• HLL
receives National Award for Excellence in Cost Management instituted by ICWAI
at New Delhi on 25th January.
• Launches
MOODS Get Closer Pack on 19th March at Chennai.
• HLL
upgraded as a Schedule ‘B” PSU by the Government of India on 24th April.
• Launches
a new contraceptive concept - the Confidom Passion Rings – a women
initiated barrier method made of polyurethane at Bangalore on May 6.
• Launches
break after use syringe - ‘Bsure’ at a Mumbai on 11th June.
• HLL
declared a MINI RATNA PSE by the Government of India on 31st August.
• TYFEX
and HIVAC-B Vaccines launched by Union Secretary, Health and Family Welfare
at New Delhi on 30th October.
• HLL
ties up with SUPPLYCO in Kerala for the distribution of its products on
9th November.
• HLL
receives the Kite Mark (UK) Certification for its Condoms on 16th
November.
• KFB
receives the National Energy Conservation Award in the Drugs and
Pharmaceuticals sector on 14th December.
2007
• HLL
renovates and opens the Kowdiar Park at Thiruvananthapuram for the
citizens of Kerala’s Capital city on 17th January.
• HLL
forms Infrastructure Development Division in February.
• HLL
organized its first ever inter Unit/Department Expo - Latexpo 2007 at
PFT from 22-24th February.
• Launches
‘Crezendo’ Condoms with Vibrating Ring on 8th March at Chandigarh.
• Launches
Aastha Pan Flavoured Condom for Family Health International, at Mumbai
on16th July.
• Merrygold
Health Service Network launched by HLFPPT along with SIFPSA and USAID in UP
on 23rd August.
• New
Condom Plant at Peroorkada inaugurated by the Union Minister for H&FW on
24th November. With this PFT’s capacity increases to over one billion (1000
million) condoms – one of the world’s largest.
• HLL
commenced work on the Super Specialty Block of the Trivandrum Medical
College on 24th November.
• HLL’s
‘Corporate Song’ released on 24th November.
• HLL’s
In - Vitro Diagnostic Test Kits manufacturing facility at Manesar,
Gurgaon inaugurated by the Union Secretary, H&FW on 29th
November.
• Launches
‘VELVET’ – the new Female Condom made of a nitrile, on 17th December.
• HLL’s ‘Smrithivanam’ Social Forestry Programme inaugurated by Sri
T. K. A. Nair, Principal Secretary to the Prime Minister on 25th December.
2008
• The
Union Ministry of H and FW decides on setting up an Integrated Vaccine
Complex (IVC) and a Medical Equipment and device manufacturing park
(MediPark) at Chengalpet in Tamil Nadu.
• HindLabs
Diagnostic Centre inaugurated by the Union Minister for Health and Family
Welfare at the CGHS Dispensary at R. K. Puram, New Delhi on 9th February.
• Formation
of LifeSpring Hospitals (Private) Limited - a joint venture between
Subject and Acumen Fund, USA, formed on 18th March.
• Second
LifeSpring Hospital, at Mallappur near Hyderabad inaugurated on
16th June and the third Hospital at Nellore on 20th June, the fourth at Vijayawada
on 14th August and the fifth at Vanasthalipuram near Hyderabad on 24th
August.
• Subject
signs MOU for project consultancy for the Integrated Vaccine Complex
with NNE Pharmaplan and for the MediPark with IL and FS on 21st August.
• Sri
O. B. Parissh, President, Female Health Company, US inaugurates the Female
Condom manufacturing facility at Kakkanad, Kochi (KFC), on 3rd September.
• MOU
signed with the Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, for
setting up of Technology Business Incubation Centre, on 4th
September.
• Receives
National Rajbasha Award from the President of India for outstanding
implementation of Official Language in the Southern Region, on 14th September.
• Subject
registered its first Pharma product outside India in Peru in South America and
launches its once-a-week, non-steroidal oral contraceptive pill in the brand
name ‘Ivy Femme’ in Lima, Peru, on 15th October.
• Subject
signs an MOU with the Government of Kerala for the setting up of three MRI
Scan Centres at Thrissur, Alapuzha and Kottayam Medical Colleges on 1st
November.
• Subject
ties up with Arya Vaidya Sala (AVS), Kottakkal for introducing Women
Health Care, Health Generics, and Neutraceutical products, on 5th December
• Receives
Capexil’s Export Award for outstanding export performance for 2007-08,
on 10th December.
2009
• Hindustan
Latex - HLL - took a new name HLL Lifecare Limited – on 1st January - as an
organization whose activities encompass complete health care for all.
Changes were also brought to its existing Logo by adding a touch of pink -
which serves as the messenger of good health.
•
Launches at Jaipur, Lactohil - a health tonic to improve the health of
lactating mothers, a product from AVS, Kottakkal, on 5th January.
•
Subject opened MOODS Planet retail outlet at Thiruvananthapuram (Kerala) to
directly reach its range of contraceptives to consumers, on 16th March.
• HLL
introduces M-CARE CU 250, a superior version of CuT on 01st August.
•
HLL launched Herbs and Berries Chyavanules on 19th August 2009 at Kochi.
•
The Hindlabs MRI Scan Centre at the Thrissur Medical College inaugurated by
Kerala’s Health Minister Smt. P. K. Srimathy Teacher, on 29th August 2009.
• Subject
ties up with College of Engineering-Trivandrum (CET) to carry out programmes
for promoting industry-academic interaction, on 10 December.
• The
prestigious ‘Superbrand’ status was conferred on Subject premium condom brand
MOODS on 17 December.
2010
• Subject
second MRI Scan Centre set up by HINDLABS at the Alappuzha Medical College
inaugurated by Kerala Chief Minister Shri. V.S. Achuthananthan on 12 January.
• Subject
new office complex in the National Capital Region (NCR) in Noida, New Delhi
inaugurated by Shri.Ghulam Nabi Azad, Union Minister for Health and Family
Welfare on 14 January.
• Launched
Moods Condoms in Australia in association with M/s. Indo Pacific Enterprises
Pty Limited NSW, on 06 February.
• Foundation
stone laid for Subject corporate R and D Centre at Akkulam on 19 February.
• Launched
ERP (Enterprise Resource Planning) implementation project on 23 March.
• Subject
officers sign Value Charter founded on three core values-Trust Transparency and
Teamwork on 24 March.
• Pharma
production Facility set up at Indore for production of Tablets, Capsules and
ORS on 28 April.
• Subject
third Hindlabs MRI Scan Centre at Govt. Medical College Kottayam inaugurated by
Kerala Health Minister Smt. P.K. Sreemathy Teacher, on 17 May.
• Subject
completes the construction of Super Speciality Block in the Trivandrum Medical
College Hospital set up under the Pradhan Mantri Swasthya Suraksha Yojana
(PMSSY) on 28 May.
• Signs
MoU with National Institute of Research in Reproductive Health (NIRRH) Mumbai
for developing and up scaling technologies in the area of contraceptive and
reproductive health and subsequent commercialization of products on 01 June.
• Foundation
stone laid for Subject world class hormonal/steroidal formulation plant-UNIPILL
Block-with an investment of Rs. 40 Crore at Subject Kanagala Factory on 12
September.
• Subject bags prestigious Indira Gandhi Official Language Award first
prize among C region (non-Hindi speaking states) on 14 September.
• The
prestigious Power Brand status has been conferred on MOODS brand recognizing it
as one of the top 200 brands in India, on 01 October 2010.
• Subject
Scientist Dr. Abi S. Aprem was awarded a grant of $ 100,000 (Rupees Forty Five
Lakhs) by Bill and Melinda Gates Foundation for his project on improving the
efficacy and acceptability of Copper T, on 10 November.
2011
• Shri.
Ghulam Nabi Azad, Union Minister for Health and Family Welfare inaugurated the
second Blood Bag Plant – DONATO BLOCK- at Akkulam Factory, on 05 January 2011.
• Subject
launched two professional distance education programmes on clinical engineering
and management in association with Indira Gandhi National Open University
(IGNOU), on 05 January 2011.
• The
Union Minister for Health and Family Welfare, Sri Ghulam Nabi Azad inaugurated
on 5th January 2011, the Super Specialty Block of the Trivandrum Medical
College built by HLL's Infrastructure Development Division. This was the
first hospital upgradation project to be completed under the PMSSY.
• Smt.
Sonia Gandhi, UPA Chairperson inaugurates the HLL-HLFPPT Health Mela at
Raebareilly on 05 February 2011.
• Subject
was awarded CSR Award 2010 by Kerala Management Association on 03 February
2011.
• Subject
receives Capexil Special Export Award 2009-10.
• Subject
second contraceptive outlet “Moods Planet” opened at Technopark,
Thiruvananthapuram.
• Subject
Peroorkada Factory won first prize for Industrial safety in the large size
industries by National Safety Council (Kerala Chapter).
• Foundation
stone laid for the multi storey building at Kakkanad Factory Cochin (KFC) as
part of the Capacity Expansion Project on 09 May 2011.
• Subject
receives Performance Excellence Award – 2010 from Indian Institute of
Industrial Engineering on 16 May 2011.
• Subject
launched STAR (Sugar Testing and Review), a mobile checkup van to spread awareness
about diabetes and help people check blood glucose on 01 June 2011.
• Subject
becomes the first PSU in the Kerala to sign MoU with Petronet LNG Ltd (PLL) for
long-term procurement of LNG for its factories on 07 June 2011.
• Subject
launched largest SMS campaign on blood donation in Kerala, in association with
BSNL on 14 June 2011.
• Subject
bagged Kerala State Pollution Control Board Award for 2010-2011.
• Subject
was awarded Best CSR Project Award 2010 by Project Management Institute (PMI)
• Subject
launches “I’m not shy”, a Nation-wide confidence building campaign on condom
purchase on the World Population Day on 11 July 2011.
• Subject
enters into a technology transfer agreement with Indian Council of Medical
Research (ICMR) for manufacture of Urine based Fertility Test Kit on 02 August
2011.
• Subject
hosts Sarga Sangamam 2011, the cultural extravaganza of industrial Kerala,
on 12 August 2011.
• Receives National Rajbasha Award (second prize) from the President of India
for outstanding implementation of Official Language in the Southern Region, on
12th September 2011.
•
Sargsangamam 2011, the cultural festivity of industrial Kerala, held from 08-12
November 2011. Ten dramas competed for the top spots in the competition.
•
Shri. Ghulam Nabi Azad, Union Minister for Health and Family Welfare launched
Cycle Beads, a simple, inexpensive, non clinical and easy to use natural family
planning method, on 04 December 2011.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 50.31 |
|
|
1 |
Rs. 79.04 |
|
Euro |
1 |
Rs. 65.82 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
8 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
8 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
8 |
|
--PROFITABILIRY |
1~10 |
6 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
7 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
7 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
64 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.